NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 43.49 against a street estimate of 47.04 — a miss of 7.5%.
with an average price target of ₹5,948.55.
MIXED Q1 FY27 revenue grew 11% YoY to ₹3,740cr, beating IPM by 100bps. India growth 10.3% dragged by flat trade generics; branded grew 12%. U.S. CDMO facility received OAI warning but supplies continue. Net profit fell 21.7% due to taxes. Q1 FY27 India growth held back by flat trade generics (now facing competition from larger players). International driving company momentum via double-digit growth in Australia, Chile, other non-U.S. markets. U.S. challenged by pricing erosion and minimal volume expansion; currency helping top line only. Analysts repeatedly questioned India growth softness, U.S. volume stagnation, and CDMO profitability timeline. Management blamed trade generics competitive pressure, stressed currency headwinds in U.S., and emphasized CDMO patience (different sales cycle than pharma). CEO hiring update provided; Occlutech integration on track despite July close delay. 20…
Full summary in the app.
| Document | Date |
|---|---|
| Q1 FY27 earnings call ALKEM LABORATORIES LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Revenue from operations: INR 3,740 crores, YoY growth 11% • India sales: INR 2,497 c | 2026-08-20 |
| Investor presentation · Q1 FY27 ALKEM LABORATORIES LIMITED – Q1 FY27 RESULTS SUMMARY HEADLINE NUMBERS • Total Revenue from Operations: ₹37,402 million, up 10.9% year-over-year • EB | 2026-08-14 |
| Annual report FY2026 ALKEM LABORATORIES LIMITED – ANNUAL REPORT FY 2025-26 HEADLINE NUMBERS • Revenue from Operations FY 2025-26: ₹147,123 Million (+13.5% year-on-year) | 2026-07-29 |
| Q4 FY26 earnings call ALKEM LABORATORIES LIMITED – Q4 FY2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total Revenue FY2026: INR 1,47,123 million, Y-o-Y growth of 1 | 2026-06-01 |
| Investor presentation · Q4 FY26 ALKEM LABORATORIES Q4 FY26 & FY26 RESULTS SUMMARY HEADLINE NUMBERS • FY26 Total Revenue: ₹147,123 million – YoY growth of 13.5% • FY26 EBITDA: ₹30,0 | 2026-05-28 |
| Quarterly results · Q4 FY26 DOCUMENT SUMMARY: ALKEM LABORATORIES LIMITED HEADLINE NUMBERS • No financial numbers provided in this document BUSINESS & SEGMENT HIGHLIGHTS • No bu | 2026-04-10 |
| Investor presentation ALKEM MEDTECH STRATEGIC PRESENTATION SUMMARY HEADLINE NUMBERS • Global MedTech market size: $680 billion (2025), projected to reach $870 billion by | 2026-02-18 |
| Q3 FY26 earnings call ALKEM LABORATORIES Q3 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue: INR 37,368 million, Y-o-Y growth 10.7% • International sales: INR 12,1 | 2026-02-16 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹10 / share ex-date Aug 7, 2026 | 2026-08-07 |
| Dividend | ₹43 / share ex-date Feb 20, 2026 | 2026-02-20 |
| Announcement | Date |
|---|---|
| Disclosure under Regulation 30 regarding acquisition updates Alkem Laboratories Limited, a major Indian pharmaceutical company, has announced an acquisition under SEBI disclosure regulations. The company has informed the stock exchange about this corp | 2026-07-17 |
| Disclosure of acquisition update under SEBI LODR Regulations Alkem Laboratories Limited has announced an acquisition, disclosed under SEBI regulations. While the full details of the acquisition target, purchase price, and strategic rationale are not p | 2026-06-29 |
| Increased investment for new manufacturing facility in Ujjain Alkem Laboratories, a major pharmaceutical company, has announced an increased investment in a new manufacturing facility in Ujjain, Madhya Pradesh. This expansion represents the company's c | 2026-04-02 |
| Allotment of land for new greenfield formulation manufacturing facility in Ujjain Alkem Laboratories Limited has received approval for land allotment in Ujjain, Madhya Pradesh to build a new manufacturing facility for producing pharmaceutical formulations from scratch (gr | 2026-03-18 |
| Updates on acquisition of another business or stake Alkem Laboratories Limited has informed the Exchange about Updates on Acquisition. | 2026-03-06 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alkem Laboratories Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.